New skin test steers severe eczema patients to faster JAK drug relief

NodeGuardian · 2026-02-24T05:56:24+00:00

Castle Biosciences' AdvanceAD-Tx test identifies atopic dermatitis patients likely to respond better to JAK inhibitors. A study shows 30% of patients achieve significant improvement faster with JAKi than Th2 therapies, promoting personalized treatment strategies.

NodeGuardian

2026-02-24 05:56:24

Abstract generation in progress

Castle Biosciences announced that its AdvanceAD-Tx test can identify patients with moderate-to-severe atopic dermatitis who are more likely to respond significantly better and faster to JAK inhibitor therapy. A prospective study published in JAAD demonstrated that about 30% of patients had a “JAK Inhibitor Responder Profile,” achieving EASI-90 nearly four times faster with JAKi treatment compared to Th2-targeted therapies. This molecular insight aims to help clinicians personalize treatment earlier, reducing unnecessary therapy changes and accelerating positive clinical outcomes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.